Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to Wee1-like protein kinase (Wee1) targeting moiety via linker acting as Wee1 degradation inducers reported to be useful for the treatment of cancer.
Lynk Pharmaceuticals Co. Ltd. has disclosed nitrogen-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Nearly five years after submitting its first NDA seeking U.S. approval for Vanflyta (quizartinib) for treating a subset of patients with acute myeloid leukemia (AML), Daiichi Sankyo Co. Ltd. finally cleared the last hurdle. The FDA on July 20 approved the FLT3 inhibitor for use in combination with cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed disease that is FLT3 ITD-positive.
Prestige Biopharma Ltd. is mounting efforts to rise rank through the industry with a two-pronged strategy of becoming a global cancer antibody drug developer and contract development and manufacturing organization.
The overexpression of the MYC oncogene could be explained through a new pathway that would act before transcription, when MYC binds to DNA. A group of scientists from Spain have identified how the ERK2 kinase interacted with the CDK9 protein, enabling it to bind to DNA in the promoter region of MYC.
Shanghai Euregen Biopharma Co. Ltd. has described pyridazine compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has identified immunostimulatory antibody-drug conjugates (ISAC) comprising immunomodulators (Toll-like receptor 7 [TLR7] and/or TLR8 agonists) bound to antibodies through cleavable or uncleavable linkers reported to be useful for the treatment of cancer.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceuticals Co. Ltd. have disclosed antibody-drug conjugates (ADC) comprising human monoclonal antibodies targeting ROR1 covalently linked to exatecan through a linker. They are reported to be useful for the treatment of cancer.
RSS
